{"id":51256,"date":"2022-11-25T16:02:14","date_gmt":"2022-11-25T15:02:14","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/united-states-liquid-biopsy-market-report-2022-industry-trends-growth-outlook-impact-of-covid-19-company-analysis-2021-2027-researchandmarkets-com\/"},"modified":"2022-11-25T16:02:14","modified_gmt":"2022-11-25T15:02:14","slug":"united-states-liquid-biopsy-market-report-2022-industry-trends-growth-outlook-impact-of-covid-19-company-analysis-2021-2027-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/united-states-liquid-biopsy-market-report-2022-industry-trends-growth-outlook-impact-of-covid-19-company-analysis-2021-2027-researchandmarkets-com\/","title":{"rendered":"United States Liquid Biopsy Market Report 2022: Industry Trends, Growth, Outlook, Impact of COVID-19, Company Analysis 2021-2027 – ResearchAndMarkets.com"},"content":{"rendered":"
\n

DUBLIN–(BUSINESS WIRE)–The “United States Liquid Biopsy Market, Size, Global Forecast 2022-2027, Industry Trends, Growth, Outlook, Impact of COVID-19, Company Analysis”<\/a> report has been added to ResearchAndMarkets.com’s<\/strong> offering.\n<\/p>\n

<\/a><\/p>\n

\nUnited States Liquid Biopsy Market reached US$ 305.4 Million in 2021 and is expected to reach US$ 803.8 Million by 2027, expanding at a CAGR of 17.50% during 2021-2027\n<\/p>\n

\nLiquid biopsy is the molecular examination of nucleic acids, subcellular structures, particularly exosomes, and, in the case of cancer, circulating tumor cells in bodily fluids. Liquid biopsy has been the subject of intense research over the last ten years to develop a less invasive and more precise individualized therapy.\n<\/p>\n

\nFurthermore, due to its sophisticated nature, which includes a short turnaround time and feasibility and the capacity to do early cancer screening, liquid biopsies are becoming more popular in the United States.\n<\/p>\n

\nUnited States Liquid Biopsy Market Size<\/strong>\n<\/p>\n

\nThe liquid biopsy methods are minimally invasive and cost-effective in the United States. As a result, they are a popular alternative for cancer diagnosis among Americans.\n<\/p>\n

\nOther essential driving factors influencing the US liquid biopsy market in the projected period include an increase in patient demand for non-invasive treatment procedures and the number of cancer patients. However, the reduced sensitivity of some liquid biopsies may limit market growth in the United States throughout the foreseeable period.\n<\/p>\n

\nHow COVID-19 Affected United States Liquid Biopsy Industry<\/strong>\n<\/p>\n

\nThe coronavirus outbreak damaged the US biopsy diagnostics centers, hospitals, supply chains, and clinical trials. As a result, cancer diagnoses were being delayed since clinics had been closed since the start of the COVID-19 pandemic, and diagnosis and screening services were growing slower. In addition, cancer patients had numerous obstacles outside of the pandemic, including increased susceptibility to severe infection and disruptions in treatment or routine medical care.\n<\/p>\n

\nLung Cancer Accounts for The Dominant Market Share in The Forecast Period<\/strong>\n<\/p>\n

\nThe liquid biopsy market in the United States is split into four categories: lung cancer, breast cancer, colorectal cancer, and prostate cancer.\n<\/p>\n

\nLung cancer is expected to have the largest market share during the projection period. According to the American Cancer Society, non-small-cell lung cancer, the most frequent kind of lung cancer in the United States, will be diagnosed in 235,760 persons in 2021. Lung cancer affects one in every 17 men and one in every 15 women at some point in their lives.\n<\/p>\n

\nBy Product, Assay Kits Holds the Largest Market Share<\/strong>\n<\/p>\n

\nThe liquid biopsy market in the United States is classified into three categories: kits and consumables, instruments, and services.\n<\/p>\n

\nThe kits and consumables are expected to have the most significant market share during the projection period. In the projection period, demand for kits and consumables will be driven by the ability to repeat sampling for liquid biopsy and their convenience and affordability.\n<\/p>\n

\nCirculating Tumor Cells Maintains Their Dominance<\/strong>\n<\/p>\n

\nThe liquid biopsy market in the United States is classified into Circulating tumor cells (CTCs), Circulating tumor DNA (ctDNA), Extracellular vesicles (EVs), and Other biomarkers based on the circulating biomarker (cell-free DNA, etc.).\n<\/p>\n

\nCircular tumor cells are expected to maintain their dominance throughout the predicted period. The market demand for Circulating tumor DNA is being driven by the rising frequency of cancer and the introduction of ctDNA-based liquid biopsy analysis, which can evaluate prognosis and tumor progression (ctDNA).\n<\/p>\n

\nKey Companies Insights<\/strong>\n<\/p>\n

\nThermo Fisher Scientific Inc, Roche Diagnostics, Bio-Rad Laboratories Inc, Biocept, Inc., Biocartis, Myriad Genetics, Inc., Exact Sciences (Genomic Health), NeoGenomics Laboratories, Quest Diagnostic Inc, and Qiagen are among the important players profiled in our report. These market players in the United States contribute to market growth by diversifying their cancer diagnostics portfolios, resulting in increased demand for their biopsy test kits.\n<\/p>\n

\nOther Segment Covered in Our Report Includes the Following<\/strong>\n<\/p>\n